ʻO Sacubitril Hemicalcium
沙库比曲半钙盐 | ʻO Sacubitril Hemicalcium | 1369773-39-6 | I-Hale |
沙库比曲钠盐 | 149690-05-1 | I-Hale | |
LCZ-4 | 1426129-50-1 | I-Hale | |
LCZ-7 | 1012341-48-8 | I-Hale | |
LCZ-8 | 1012341-50-2 | I-Hale | |
LCZ-9 | 149690-12-0 | I-Hale |
Ka hope
ʻO ka paʻakai hemicalcium AHU-377 he ʻano paʻakai hemicalcium o AHU-377.He mea hoʻopale ia o neprilysin me ka waiwai IC50 o 5 nM [1].
AHU-377 a me ka angiotensin II AT1 receptor antagonist valsartan haku LCZ696 i ka 1:1 molar ratio.ʻO LCZ696 kahi mea hoʻopaneʻe neprilysin receptor angiotensin.Hiki iā ia ke hōʻemi i ke kahe koko a he lāʻau hou paha ia no ka mālama ʻana i ka hemahema o ka naʻau.ʻO ka AHU-377 kahi lāʻau lapaʻau, hiki ke hoʻololi ʻia e ka enzymatic cleavage o ka ethyl ester i loko o ke ʻano hana LBQ657.Ua hōʻike ʻia ʻo AHU-377(30 a me 100 mg/kg, PO) hiki ke hana i ka hopena antihypertensive ma ke ʻano i hilinaʻi ʻia i nā ʻiole DAHI-SS.Akā i ka DOCA-salt hypertensive rats, hōʻike ia i kahi hōʻemi nāwaliwali [2, 3].
Kuhikuhi:
[1] Ksander GM, Ghai RD, deJesus R, Diefenbacher CG, Yuan A, Berry C, Sakane Y, Trapani A. Dicarboxylic acid dipeptide neutral endopeptidase inhibitors.J Med Chem.1995 Mei 12;38(10):1689-700.
[2] Voors AA, Dorhout B, van der Meer P. ʻO ke kuleana kūpono o valsartan + AHU377 (LCZ696) i ka mālama ʻana i ka naʻau.Opin Investig Drugs.2013 ʻAukake;22(8):1041-7.
[3] Laxminarayan G Hegde, Cecile Yu, Cheruvu Madhavi et al.Hoʻohālikelike ka maikaʻi o ka AHU-377, he mea hoʻopaneʻe neprilysin ikaika, ma nā ʻano ʻiole ʻelua o ke kiʻekiʻe e pili ana i ka nui.BMC Pharmacology 2011, 11(Suppl 1):P33.
ʻO ke kinona
Manaʻo18Nā papahana Loiloi Kūlike Kūlike i ʻae ʻia4, a6nā papahana ma lalo o ka ʻae ʻia.
Ua hoʻokumu ka ʻōnaehana hoʻokele maikaʻi honua kiʻekiʻe i ke kumu kūʻai.
Holo ka nānā ʻana i ka maikaʻi ma ke ola holoʻokoʻa o ka huahana e hōʻoia i ka maikaʻi a me ka hopena therapeutic.
Kākoʻo ka hui ʻoihana Regulatory Affairs i nā koi maikaʻi i ka wā o ke noi a me ke kau inoa ʻana.